Form D · Biotechnology
ALZHEON, INC.
Framingham, MA · CIK 0001582636
Offering snapshot reported Sep 10, 2026 · SEC filing
- Reported sold
- $78.8M Offering amount: $500M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 26, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 10, 2026 | Initial | $78,797,184 | No comparison | 3 | SEC filing |
| Feb 10, 2025 | Amendment | $126,259,938 | $1,259,907vs Jan 2, 2025 | 76 | SEC filing |
| Jan 2, 2025 | Amendment | $125,000,031 | $107,750,140vs Mar 12, 2024 | 76 | SEC filing |
| Mar 12, 2024 | Initial | $17,249,891 | No comparison | 2 | SEC filing |
| Jan 11, 2023 | Initial | $1,703,768 | No comparison | 6 | SEC filing |
| Sep 30, 2020 | Initial | $2,432,016 | No comparison | 5 | SEC filing |
| Jan 15, 2020 | Initial | $6,163,716 | No comparison | 13 | SEC filing |
| Sep 5, 2018 | Amendment | $19,801,820 | $4,037,721vs Jun 9, 2017 | 81 | SEC filing |
| Jun 9, 2017 | Initial | $15,764,099 | No comparison | 63 | SEC filing |
| Feb 26, 2016 | Initial | $1,300,000 | No comparison | 3 | SEC filing |
| Jul 27, 2015 | Initial | $6,905,000 | No comparison | 26 | SEC filing |
| Feb 25, 2015 | Amendment | $7,344,629 | $4,294,629vs Jan 9, 2015 | 60 | SEC filing |
| Jan 9, 2015 | Initial | $3,050,000 | No comparison | 12 | SEC filing |
| Dec 16, 2013 | Amendment | $550,000 | $220,000vs Jul 31, 2013 | 8 | SEC filing |
| Jul 31, 2013 | Initial | $330,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-597067
Source: Form D, filed Sep 10, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Susan Abushakra, M.D. | Executive |
| Michael Aceti | Executive |
| Adem Albayrak | Executive |
| Menghis Bairu | Director |
| Franklin Berger | Director |
| Adam Hale Brockman | Executive |
| Christopher Noel Dunn | Director |
| Noel Dunn | Director |
| Neil W. Flanzraich | Director |
| Jean Pierre Garnier | Director |
| Franz Hefti | Director |
| Jordan Heller | Director |
| John Hey | Executive |
| John Hey, Ph.D. | Executive |
| Diane K. Jorkasky, M.D. | Director |
| Dennis Langer | Director |
| Ken Mace | Executive |
| Kenneth Mace | Executive |
| Gregory Leon Miller | Executive |
| Scott Minick | Director |
| David Nikodem | Director |
| David Nikodem, Ph.D. | Director |
| Glenn E. Pauly | Executive |
| Aidan Power, Mrc Psych | Executive |
| Gino Santini | Director |
| Muneer Sateer | Director |
| Muneer Satter | Director |
| Robert Silverman | Executive |
| Jean Pierre Sommadossi | Director |
| Martin Tolar | Director, Executive |
| Martin Tolar, M.D., Ph.D. | Director, Executive |
| Mark Versavel | Executive |
| Jeremy Yongxin Yu | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
111 Speen Street Suite 306
Framingham, MA, 01701
Phone: 508-861-7709
Framingham, MA, 01701
Phone: 508-861-7709